ID   AK1CA_RAT               Reviewed;         324 AA.
AC   D3ZF77;
DT   10-OCT-2018, integrated into UniProtKB/Swiss-Prot.
DT   20-APR-2010, sequence version 1.
DT   24-JUL-2024, entry version 95.
DE   RecName: Full=Aldo-keto reductase family 1 member C15 {ECO:0000305};
DE            EC=1.1.1.- {ECO:0000269|PubMed:17574202, ECO:0000269|PubMed:21187079, ECO:0000269|PubMed:21187080};
DE            EC=1.1.1.216 {ECO:0000269|PubMed:17574202, ECO:0000269|PubMed:21187079};
DE   AltName: Full=RAKc {ECO:0000303|PubMed:7511002};
GN   Name=Akr1c15 {ECO:0000303|PubMed:17574202, ECO:0000312|RGD:1307514};
GN   Synonyms=Akr1cl {ECO:0000312|RGD:1307514};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116 {ECO:0000312|Proteomes:UP000002494};
RN   [1] {ECO:0000312|Proteomes:UP000002494}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway {ECO:0000312|Proteomes:UP000002494};
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [2] {ECO:0000312|EMBL:EDL78576.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000305}
RP   IDENTIFICATION, AND TISSUE SPECIFICITY.
RX   PubMed=7511002; DOI=10.1021/bi00177a012;
RA   Qin K.N., Cheng K.C.;
RT   "Structure and tissue-specific expression of the aldo-keto reductase
RT   superfamily.";
RL   Biochemistry 33:3223-3228(1994).
RN   [4] {ECO:0000305}
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, SUBUNIT, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17574202; DOI=10.1016/j.abb.2007.05.008;
RA   Endo S., Matsunaga T., Horie K., Tajima K., Bunai Y., Carbone V.,
RA   El-Kabbani O., Hara A.;
RT   "Enzymatic characteristics of an aldo-keto reductase family protein
RT   (AKR1C15) and its localization in rat tissues.";
RL   Arch. Biochem. Biophys. 465:136-147(2007).
RN   [5] {ECO:0000305}
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR
RP   LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=21187079; DOI=10.1016/j.cbi.2010.12.017;
RA   Endo S., Matsunaga T., Ohta C., Soda M., Kanamori A., Kitade Y., Ohno S.,
RA   Tajima K., El-Kabbani O., Hara A.;
RT   "Roles of rat and human aldo-keto reductases in metabolism of farnesol and
RT   geranylgeraniol.";
RL   Chem. Biol. Interact. 191:261-268(2011).
RN   [6] {ECO:0000305}
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=21187080; DOI=10.1016/j.cbi.2010.12.018;
RA   Matsunaga T., Shinoda Y., Inoue Y., Endo S., El-Kabbani O., Hara A.;
RT   "Protective effect of rat aldo-keto reductase (AKR1C15) on endothelial cell
RT   damage elicited by 4-hydroxy-2-nonenal.";
RL   Chem. Biol. Interact. 191:364-370(2011).
CC   -!- FUNCTION: Catalyzes the NADPH-dependent reduction of a variety of
CC       substrates including aromatic and aliphatic aldehydes, quinones,
CC       ketones, dicarbonyl compounds and 17-ketosteroids (PubMed:17574202).
CC       Catalyzes the NADP(+)-dependent oxidation of aromatic, alicyclic and
CC       aliphatic alcohols, and 17beta-hydroxysteroids (PubMed:17574202). To a
CC       lesser extent, can also catalyze the reduction of some aldoses and
CC       ketoses and the oxidation of some sugar alcohols (PubMed:17574202). In
CC       the stomach, lung and colon tissues, mediates the reduction of farnesal
CC       and geranylgeranial into farnesol and geranylgeraniol respectively
CC       (PubMed:21187079). By reducing 4-hydroxy-2-nonenal (HNE), produced
CC       during lipid peroxidation, into 1,4-dihydro-2-nonene (DHN), protects
CC       vascular endothelial cells from damage elicited by oxidized
CC       lipoproteins (PubMed:21187080). {ECO:0000269|PubMed:17574202,
CC       ECO:0000269|PubMed:21187079, ECO:0000269|PubMed:21187080}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(2E,6E)-farnesol + NADP(+) = (2E,6E)-farnesal + H(+) + NADPH;
CC         Xref=Rhea:RHEA:14697, ChEBI:CHEBI:15378, ChEBI:CHEBI:15894,
CC         ChEBI:CHEBI:16619, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         EC=1.1.1.216; Evidence={ECO:0000269|PubMed:17574202,
CC         ECO:0000269|PubMed:21187079};
CC   -!- ACTIVITY REGULATION: The dehydrogenase activity is inhibited by
CC       3',3'',5',5''-tetraiodophenolphthalein, phenolphthalein, genistein,
CC       quercetin, zearalenone and diethylstilbestrol.
CC       {ECO:0000269|PubMed:17574202}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.2 uM for 4-nitrobenzaldehyde {ECO:0000269|PubMed:17574202};
CC         KM=3.1 uM for benzaldehyde {ECO:0000269|PubMed:17574202};
CC         KM=20 uM for pyridine-4-aldehyde {ECO:0000269|PubMed:17574202};
CC         KM=25 uM for 2-phenyl-2-propenal {ECO:0000269|PubMed:17574202};
CC         KM=2.4 uM for NADP(+) {ECO:0000269|PubMed:17574202};
CC         KM=1430 uM for NAD(+) {ECO:0000269|PubMed:17574202};
CC         KM=0.6 uM for NADPH {ECO:0000269|PubMed:17574202};
CC         KM=43 uM for NADH {ECO:0000269|PubMed:17574202};
CC         KM=0.3 uM for 1-decanal {ECO:0000269|PubMed:17574202};
CC         KM=0.9 uM for 1-nonanal {ECO:0000269|PubMed:17574202};
CC         KM=1.1 uM for 1-octanal {ECO:0000269|PubMed:17574202};
CC         KM=1.1 uM for 1-hexanal {ECO:0000269|PubMed:17574202};
CC         KM=112 uM for D-lactoaldehyde {ECO:0000269|PubMed:17574202};
CC         KM=125 uM for L-lactoaldehyde {ECO:0000269|PubMed:17574202};
CC         KM=225 uM for 4-methylpentanal (isocaproaldehyde)
CC         {ECO:0000269|PubMed:17574202};
CC         KM=0.4 uM for all-trans-retinal {ECO:0000269|PubMed:17574202};
CC         KM=3.5 uM for trans-2,4-nonadienal {ECO:0000269|PubMed:17574202};
CC         KM=3.3 uM for trans-2-nonenal {ECO:0000269|PubMed:17574202};
CC         KM=2.3 uM for 9-cis-retinal {ECO:0000269|PubMed:17574202};
CC         KM=2.5 uM for 4-hydroxy-2-nonenal (HNE)
CC         {ECO:0000269|PubMed:17574202};
CC         KM=0.8 uM for 6-tert-butyl-2,3-epoxy-4-benzoquinone (TBE)
CC         {ECO:0000269|PubMed:17574202};
CC         KM=2.7 uM for 1,4-naphthoquinone {ECO:0000269|PubMed:17574202};
CC         KM=14 uM for 5-hydroxy-1,4-naphthoquinone (juglone)
CC         {ECO:0000269|PubMed:17574202};
CC         KM=22 uM for 1-indanone {ECO:0000269|PubMed:17574202};
CC         KM=22 uM for 3-hydroxy-2-butanone {ECO:0000269|PubMed:17574202};
CC         KM=0.5 uM for 1H-indole-2,3-dione (isatin)
CC         {ECO:0000269|PubMed:17574202};
CC         KM=0.6 uM for 16-ketoestrone {ECO:0000269|PubMed:17574202};
CC         KM=2 uM for 2,3-hexanedione {ECO:0000269|PubMed:17574202};
CC         KM=5.5 uM for butane-2,3-dione (diacetyl)
CC         {ECO:0000269|PubMed:17574202};
CC         KM=16 uM for methylglyoxal {ECO:0000269|PubMed:17574202};
CC         KM=30 uM for 21-dehydrocortisol {ECO:0000269|PubMed:17574202};
CC         KM=12 uM for S-indan-1-ol {ECO:0000269|PubMed:17574202};
CC         KM=32 uM for farnesol {ECO:0000269|PubMed:17574202};
CC         KM=5.6 uM for farnesal {ECO:0000269|PubMed:17574202};
CC         KM=16 uM for geranylgeraniol {ECO:0000269|PubMed:17574202};
CC         KM=0.2 uM for geranylgeranial {ECO:0000269|PubMed:21187079};
CC         KM=15 uM for 1-nonanol {ECO:0000269|PubMed:17574202};
CC         KM=8.2 uM for 1-decanol {ECO:0000269|PubMed:17574202};
CC         KM=11 uM for 5-beta-androstane-3,17-dione (etiocholanedione)
CC         {ECO:0000269|PubMed:17574202};
CC         KM=8.7 uM for 5-alpha-androstane-3,17-dione (androstanedione)
CC         {ECO:0000269|PubMed:17574202};
CC         KM=5.6 uM for 4-androstene-3,17-dione {ECO:0000269|PubMed:17574202};
CC         KM=36 uM for 5-alpha-androstan-3alpha-ol-17-one
CC         {ECO:0000269|PubMed:17574202};
CC         KM=8.7 uM for 5-beta-androstan-3alpha-ol-17-one
CC         {ECO:0000269|PubMed:17574202};
CC         KM=8.5 uM for 5-beta-androstane-3alpha,17beta-diol
CC         {ECO:0000269|PubMed:17574202};
CC         KM=12 uM for 5-beta-androstan-17beta-ol-3-one
CC         {ECO:0000269|PubMed:17574202};
CC         KM=6.9 uM for 5-alpha-androstane-3-alpha,17-beta-diol
CC         {ECO:0000269|PubMed:17574202};
CC         KM=18 uM for testosterone {ECO:0000269|PubMed:17574202};
CC         KM=18 uM for 5-alpha-androstan-17beta-ol-3-one
CC         {ECO:0000269|PubMed:17574202};
CC       pH dependence:
CC         Optimum pH is 10.5 for the dehydrogenase activity. Optimum pH is 6
CC         for the reductase activity. {ECO:0000269|PubMed:17574202};
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:17574202}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17574202,
CC       ECO:0000269|PubMed:21187079}.
CC   -!- TISSUE SPECIFICITY: Expressed in lung, specifically in bronchiolar club
CC       cells, type II alveolar cells and epithelial cells of the duct of the
CC       bronchial gland (at protein level) (PubMed:17574202, PubMed:21187079,
CC       PubMed:7511002). Expressed in gastric parietal cells and in epithelial
CC       cells of the large intestine and colon (at protein level)
CC       (PubMed:17574202, PubMed:21187079). Expressed in brown adipocytes (at
CC       protein level) (PubMed:17574202). Expressed in vascular endothelial
CC       cells (at protein level) (PubMed:17574202).
CC       {ECO:0000269|PubMed:17574202, ECO:0000269|PubMed:21187079,
CC       ECO:0000269|PubMed:7511002}.
CC   -!- SIMILARITY: Belongs to the aldo/keto reductase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AABR07028443; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH473990; EDL78576.1; -; Genomic_DNA.
DR   RefSeq; NP_001103370.1; NM_001109900.1.
DR   AlphaFoldDB; D3ZF77; -.
DR   SMR; D3ZF77; -.
DR   STRING; 10116.ENSRNOP00000055113; -.
DR   iPTMnet; D3ZF77; -.
DR   PhosphoSitePlus; D3ZF77; -.
DR   PaxDb; 10116-ENSRNOP00000055113; -.
DR   PeptideAtlas; D3ZF77; -.
DR   Ensembl; ENSRNOT00000058312.4; ENSRNOP00000055113.2; ENSRNOG00000021735.6.
DR   GeneID; 361267; -.
DR   KEGG; rno:361267; -.
DR   UCSC; RGD:1307514; rat.
DR   AGR; RGD:1307514; -.
DR   CTD; 361267; -.
DR   RGD; 1307514; Akr1c15.
DR   eggNOG; KOG1577; Eukaryota.
DR   GeneTree; ENSGT00940000163184; -.
DR   HOGENOM; CLU_023205_0_0_1; -.
DR   InParanoid; D3ZF77; -.
DR   OMA; LIYGNEH; -.
DR   OrthoDB; 890110at2759; -.
DR   PhylomeDB; D3ZF77; -.
DR   TreeFam; TF106492; -.
DR   PRO; PR:D3ZF77; -.
DR   Proteomes; UP000002494; Chromosome 17.
DR   Proteomes; UP000234681; Chromosome 17.
DR   Bgee; ENSRNOG00000021735; Expressed in lung and 18 other cell types or tissues.
DR   ExpressionAtlas; D3ZF77; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0004033; F:aldo-keto reductase (NADPH) activity; IDA:UniProtKB.
DR   GO; GO:0004032; F:aldose reductase (NADPH) activity; IBA:GO_Central.
DR   GO; GO:0047886; F:farnesol dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0047086; F:ketosteroid monooxygenase activity; IBA:GO_Central.
DR   GO; GO:0016229; F:steroid dehydrogenase activity; IBA:GO_Central.
DR   GO; GO:0008202; P:steroid metabolic process; IBA:GO_Central.
DR   CDD; cd19108; AKR_AKR1C1-35; 1.
DR   Gene3D; 3.20.20.100; NADP-dependent oxidoreductase domain; 1.
DR   InterPro; IPR020471; AKR.
DR   InterPro; IPR044482; AKR1C.
DR   InterPro; IPR018170; Aldo/ket_reductase_CS.
DR   InterPro; IPR023210; NADP_OxRdtase_dom.
DR   InterPro; IPR036812; NADP_OxRdtase_dom_sf.
DR   PANTHER; PTHR11732:SF383; ALDO-KETO REDUCTASE FAMILY 1 MEMBER C15; 1.
DR   PANTHER; PTHR11732; ALDO/KETO REDUCTASE; 1.
DR   Pfam; PF00248; Aldo_ket_red; 1.
DR   PIRSF; PIRSF000097; AKR; 1.
DR   PRINTS; PR00069; ALDKETRDTASE.
DR   SUPFAM; SSF51430; NAD(P)-linked oxidoreductase; 1.
DR   PROSITE; PS00798; ALDOKETO_REDUCTASE_1; 1.
DR   PROSITE; PS00062; ALDOKETO_REDUCTASE_2; 1.
DR   PROSITE; PS00063; ALDOKETO_REDUCTASE_3; 1.
PE   1: Evidence at protein level;
KW   Cytoplasm; NADP; Oxidoreductase; Reference proteome.
FT   CHAIN           1..324
FT                   /note="Aldo-keto reductase family 1 member C15"
FT                   /id="PRO_0000445546"
FT   ACT_SITE        56
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000255|PIRSR:PIRSR000097-1"
FT   BINDING         24..26
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:O60218"
FT   BINDING         51
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:O60218"
FT   BINDING         118
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000255|PIRSR:PIRSR000097-2"
FT   BINDING         167..168
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:O60218"
FT   BINDING         191
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:O60218"
FT   BINDING         217..225
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:O60218"
FT   BINDING         269..281
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:O60218"
FT   SITE            85
FT                   /note="Lowers pKa of active site Tyr"
FT                   /evidence="ECO:0000255|PIRSR:PIRSR000097-3"
SQ   SEQUENCE   324 AA;  37195 MW;  851BFF1FD9476B13 CRC64;
     MDLKHSRSVK LNDGNLMPVL GFGTFASKEI PKSKAAEATK VAIDVGFRHI DAAYFYQNEE
     EVGQALRDKM ADGTVKREDL FYTTKIWITF LRPELVRQCL ERSLKKLGLD YVDLCIIHIP
     IAMKPGEELL PKDANGKFIF DTVDIRDTWE ALEKCKDAGL SKSIGVSNFN HKQLELILNK
     PRLKYKPTCN QVECHPYLNQ SKLLEFCKSK DIVLVAYSAL GSHRDSSWVS SDSPYLLEDP
     VLMTIAKKHN QTPGQVALRY QLQRGVVVLA KSFNEKRIKE NFQVFDFELT PEDMKTIDSL
     NRNFRYSQMA FALDHPDYPF LEEY
//
